• Isis Pharmaceuticals Inc., of Carlsbad, Calif., and Genzyme Corp., of Cambridge, Mass., a unit of Sanofi SA, reported two-year data from a Phase III long-term extension study showing that Kynamro (mipomersen) maintained robust reductions in LDL-C in patients, as well as reductions in all other Apo B-containing atherogenic lipoproteins measured, with a safety profile consistent with the Phase III studies.